7.195
Amneal Pharmaceuticals Inc stock is traded at $7.195, with a volume of 347.12K.
It is up +0.96% in the last 24 hours and down -16.88% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.13
Open:
$7.23
24h Volume:
347.12K
Relative Volume:
0.21
Market Cap:
$2.26B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-10.57
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+0.39%
1M Performance:
-16.88%
6M Performance:
-15.32%
1Y Performance:
+34.04%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AMRX
Amneal Pharmaceuticals Inc
|
7.195 | 2.26B | 2.68B | -184.45M | 229.23M | -0.6805 |
![]()
ZTS
Zoetis Inc
|
150.26 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
HLN
Haleon Plc Adr
|
10.47 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.99 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
290.66 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Mar-08-21 | Upgrade | Goldman | Sell → Buy |
Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
Jul-27-20 | Initiated | Goldman | Sell |
May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jun-11-19 | Initiated | Barclays | Equal Weight |
May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
Mar-20-19 | Initiated | SunTrust | Buy |
Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jul-23-18 | Initiated | Morgan Stanley | Overweight |
Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ
NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace
Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph
Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma - Clinical Oncology News
Amneal Earnings Preview: Key Updates Coming May 2 in Q1 2025 Report - Stock Titan
Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace
Amneal Announces New Data From Phase 3 Study - MarketScreener
Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com
Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan
Amneal Boruzu Subcutaneous Formulation Launch - Specialty Pharmacy Continuum
Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - BioSpace
Amneal gets expanded coverage for Parkinson’s disease drug - Seeking Alpha
Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson'S Disease Patients In The U.S. - marketscreener.com
Breakthrough: Amneal's Parkinson's Drug CREXONT Secures Game-Changing Insurance Coverage - Stock Titan
Amneal and Shilpa introduce Boruzu in US for cancer treatment - Yahoo Finance
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe
Amneal Launches BORUZU , First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire
Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) - Business Wire
Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR
Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK
Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace
Amneal to Participate at Upcoming Investor Conference - WICZ
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com India
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Canada
Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com
Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com
Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com
Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):